1 Sero-epidemiological evaluation of malaria transmission in The Gambia before and after mass

2 drug administration

3

4 Author details

- 5 Lindsey Wu¹, Julia Mwesigwa², Muna Affara³, Mamadou Bah², Simon Correa², Tom Hall⁴, James G.
- 6 Beeson^{5,6,7}, Kevin K.A. Tetteh¹, Immo Kleinschmidt^{8,9}, Umberto D'Alessandro², Chris Drakeley¹
- 7 *Corresponding author: lindsey.wu@lshtm.ac.uk
- 8 1. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Infectious Tropical Diseases,
- 9 Department of Infection Biology. London WC1E 7HT, UK.
- 10 2. Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine.
- 11 Fajara, The Gambia.
- 12 3. Bernhard Nocht Institute for Tropical Medicine (BNITM). Arusha, Tanzania.
- 13 4. St. George's University of London (SGUL). SW17 ORE, London, United Kingdom.
- 14 5. Burnet Institute. Melbourne, Victoria, 3004, Australia.
- 15 6. Central Clinical School, Monash University, Victoria, Australia
- 16 7. Department of Medicine, University of Melbourne, Victoria, Australia.
- 17 8. London School of Hygiene and Tropical Medicine (LSHTM), Faculty of Epidemiology and Population
- 18 Health, Department of Infectious Disease Epidemiology. London WC1E 7HT, UK.
- 19 9. School of Pathology, Wits Institute for Malaria Research, Faculty of Health Science, University of
- 20 Witwatersrand. Johannesburg, South Africa.
- 21
- 22 Email addresses:
- 23 LW: lindsey.wu@lshtm.ac.uk
- 24 JM: julia.mwesigwa@lshtm.ac.uk NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 25 MA: affara@bnitm.de
- 26 MB: mmbah@mrc.gm
- 27 SC: <u>scorrea@mrc.gm</u>
- 28 TH: thall@sgul.ac.uk
- 29 JGB: <u>beeson@burnet.edu.au</u>
- 30 KKAT: <u>kevin.tetteh@lshtm.ac.uk</u>
- 31 IK: <u>immo.kleinschmidt@lshtm.ac.uk</u>
- 32 UD: umberto.dalessandro@lshtm.ac.uk
- 33 CD: <u>chris.drakeley@lshtm.ac.uk</u>
- 34
- 35 Keywords: malaria, serology, mass drug administration, surveillance
- 36 Abstract: 246
- 37 Word count: 3,392
- 38
- 39

40 Abstract

41 Background

42 As The Gambia aims to achieve elimination by 2030, serological assays are a useful surveillance tool

- 43 to monitor trends in malaria incidence and evaluate community-based interventions.
- 44 Methods

Within a mass drug administration (MDA) study in The Gambia, where reduced malaria infection and clinical disease were observed after the intervention, a serological sub-study was conducted in four study villages. Spatio-temporal variation in transmission was measured with a panel of recombinant *Pf* antigens on a multiplexed bead-based assay. Village-level antibody levels were quantified as under-15 sero-prevalence, sero-conversion rates, and age-adjusted antibody acquisition rates. Antibody levels prior to MDA were assessed for association with persistent malaria infection after community chemoprophylaxis.

52 Results

53 Seasonal changes in antibodies to Etramp5.Ag1 were observed in children under 15 in two 54 transmission settings – the West Coast and Upper River Regions (4.32% and 31.30% Pf prevalence, 55 respectively). At the end of the malaria season, short-lived antibody responses to Etramp5.Ag1, GEXP18, HSP40.Ag1, EBA175 RIII-V, and Rh2.2030 were lower amongst 1-15 year olds in the West 56 57 Coast compared to the Upper River, reflecting known differences in transmission. Prior to MDA, individuals in the top 50th percentile of antibody levels had two-fold higher odds of clinical malaria 58 59 during the transmission season, consistent with previous findings where individuals infected pre-MDA 60 had 2-fold higher odds of re-infection post-MDA.

61 Conclusion

Serological markers can serve dual functions as indicators of malaria exposure and incidence. Further
 studies, particularly cluster randomised trials, can help establish standardised serological protocols to
 measure transmission across endemic settings.

65 Background

In malaria elimination settings, heterogeneity and hotspots of transmission are increasingly prevalent as disease burden declines.^{1–5} At low transmission, large proportions of the population can remain malaria free for years, while subpopulations experience multiple episodes^{3,4,6}. This presents significant challenges for the implementation of malaria interventions and clinical trials designed to evaluate them^{7,8}; if untargeted, residual transmission is likely to persist.^{5,9–11} Therefore, understanding why malaria has significantly changed in some settings, but remains unyielding in others, will be critical for guiding investments in malaria control in Sub-Saharan Africa.^{12,13}

73 The Gambia has a long history of research on the heterogeneity of malaria in West Africa. 74 Entomological and clinical data have shown spatial variation in malaria infections within two kilometres of mosquito breeding sites, where immune differences between households was 75 hypothesised to drive differences in clinical outcomes.¹⁴ Studies in The Gambia have also 76 demonstrated the impact of insecticide-treated bed nets on childhood mortality,^{15,16} with additional 77 reductions in clinical malaria when combined with chemoprophylaxis.¹⁷ Subsequently, there have 78 79 been rapid declines in incidence through the scale-up of control interventions - improved diagnosis 80 and treatment, distribution of long-lasting insecticidal nets, indoor residual spraying, and seasonal malaria chemoprevention. However, micro-epidemiological variations in transmission remain, ^{18,19} 81 82 which are increasingly relevant as The Gambia aims for malaria elimination by 2030. Sufficiently 83 sensitive diagnostics will be critical to reach this target, helping to identify foci of transmission and 84 target interventions.

Serological studies in The Gambia have described country-wide heterogeneities in malaria
transmission, where schools surveys found strong correlations between sero-prevalence and

microscopy-detectable parasitaemia.²⁰ More recently, studies based on data from Uganda and Mali have identified several serological markers of *Plasmodium falciparum (Pf)* malaria exposure that are strongly associated with clinical incidence²¹. These measures of sero-incidence have the potential to supplement existing surveillance tools to monitor transmission and evaluate the effectiveness of community interventions.

92 While serology has been used in research settings to measure malaria transmission for some time, 93 standardised antigen panels for routine surveillance have yet to be established. Furthermore, gaps in our understanding of how antibody levels reflect changes in transmission still remain. Therefore, this 94 95 study evaluates the use of antibody responses as a measure of malaria exposure and incidence, with 96 the aim to inform the future design of surveillance strategies. We used serological markers to measure 97 spatio-temporal variation in transmission in a subset of four study villages from the Malaria Transmission Dynamics Study in The Gambia, which assessed epidemiological trends in six village 98 pairs,^{18,19} followed by two years of mass drug administration (MDA) with dihydroartemisnin-99 100 piperaquine (DHA-PQ).²² A panel of recombinant *Pf* antigens was used to quantify antibody levels 101 using a multiplexed immuno-assay. Village-level serological profiles were used to describe seasonal 102 and geographical variation in antibody responses, and the association between antibody levels prior 103 to MDA and persistent malaria infection during the transmission season after MDA was also 104 estimated.

105 Methods

106 Data and sampling

107 A prospective cohort study was conducted from 2013 to 2015 in six village pairs across five 108 administrative regions - West Coast (WCR), North Bank (NBR), Lower River (LRR), Central River (CRR) 109 and Upper River (URR) Regions. *Pf* prevalence measured by PCR ranged from 2.27 to 19.60% in the 110 Central River and Upper River Regions respectively. As previously described by Mwesigwa et al,¹⁹ the 111 study aimed to understand the dynamics of malaria infection and the impact of annual MDA. All residents aged more than six months were enrolled. Monthly surveys were conducted throughout the transmission season (June to December), the dry season (April 2014) and before MDA implemented in May and June. In 2014 and 2015, one round of MDA was conducted, with DHA-PQ administered to individuals aged between six months and 75 years, according to weight-based dosing guidelines, over 6 to 14 days between May and June in the six pairs of study villages. Outcomes included incidence of clinical disease, prevalence of *Pf* infection measured by polymerase chain reaction (PCR), and factors associated with infection post-MDA.

Blood samples were collected by finger prick for haemoglobin measurement, blood smear for malaria diagnosis by microscopy, and molecular and serological analysis by dried blood spot (DBS) on filter paper (Whatman 3 Corporation, Florham Park, NJ, USA). Clinical malaria cases were identified by passive case detection (PCD) at local health facilities or in villages by study nurses; clinical malaria was defined as history of fever in the previous 24 hours or axillary temperature \geq 37·5°C and a positive rapid diagnostic test (RDT) result (Paracheck *Pf*, Orchid Biomedical System, India).

125 Serological analysis included all available samples from the WCR in Besse and N'Demban from surveys 126 done at the start of the transmission season in July 2013 (N=537) and at the end of the season in 127 December 2013 (N=526). In the URR, analysis included all samples collected in Njaiyal and Madina 128 Samako in July 2013 (N=779), December 2013 (N=632), April (dry season) 2014 (N=823), and 129 December 2014 (N=757). These regions are at the extreme of transmission intensity found in The 130 Gambia - low in WCR and moderate in URR - with months selected at the start and end of the transmission season. Samples from clinical PCD cases were linked by study participant identification 131 132 code to samples from the same individuals collected during routine monthly surveys. Samples 133 collected as part of the Malaria Transmission Dynamics Study and subset of samples for serological 134 analysis are described in Figure 1.

135 Laboratory procedures

136 A full description of laboratory methods, including antigen amino acid range, selection and expression platform, are detailed in Wu et al²³ and Mwesigwa et al²⁴. Briefly, serum samples were eluted from 137 6mm DBS (8 μL whole blood equivalent) and prepared as a 1:500 dilution. Two wells on each plate 138 139 containing only antigen-coupled beads and sample buffer were included to measure background 140 signal. A pool of 22 serum samples from malaria hyper-immune individuals in The Gambia were used 141 as positive controls in a 6-point 5-fold serial dilution (1:10 - 1:31,250) and plasma samples from 142 European malaria-naive adults (1:500 dilution) as negative controls. Serum samples were processed 143 on the Luminex MAGPIX, with mean fluorescence intensity (MFI) values between plates normalised according to the protocol described in Wu et al.²⁵ 144

For diagnostic PCR, DNA was extracted from three 6-mm DBS (4 μL whole blood equivalent) using the automated QIAxtractor robot (Qiagen). Negative and positive (3D7) controls were included to control for cross contamination and DNA extraction efficiency, respectively. Extracted DNA was used in a nested PCR, amplifying multi-copy *Plasmodium* ribosomal RNA gene sequences using genus and species-specific primers. All PCR products were run using the QIAxcel capillary electrophoresis system (Qiagen).

151 Statistical analyses

Antibody responses were summarised at village level and used to describe geographical differences in transmission between WCR (low transmission) and URR (moderate-high transmission). Within each region, temporal changes were assessed using antibody responses at the start and end of transmission season (July and December 2013) and the dry season (April 2014), represented with the methods as summarised below.

Sero-prevalence and sero-conversion rate. For antigens associated with longer lived antibody responses - *P.falciparum* merozoite surface antigen 1 19-kDa carboxy-terminal region (*Pf*MSP1₁₉) and *P.falciparum* apical membrane antigen 1 (*Pf*AMA1), the distribution of MFI for all serological samples was characterised through a two-component Gaussian mixture model to define distributions of negative and positive antibody levels. Sero-positivity thresholds were defined as the mean log MFI plus two standards deviations of the negative distribution.²⁶ For antigens associated with shorter-lived antibodies – early transcribed membrane protein 5 (Etramp5.Ag1), gametocyte export protein 18 (GEXP18), heat shock protein 40 (HSP40.Ag1), erythrocyte binding antigen 175 RIII-V (EBA175), reticulocyte binding protein homologue 2 (Rh2.2030) - sero-positivity thresholds were defined by the mean log MFI plus three standard deviations of 71 malaria-naïve European blood donors used as negative controls.

Age-adjusted sero-conversion rates (SCRs), the annual rate at which sero-negative individuals become 168 169 sero-positive, were estimated for antigens associated with long-lived antibody response (PfMSP1₁₉, 170 PfAMA1). A reversible catalytic model was fitted to age-adjusted sero-positivity data using maximum 171 likelihood methods.²⁷ A common sero-reversion rate for each antigen was assumed across all villages, which was estimated based on fitting a single sero-catalytic model to all individuals and fixing the sero-172 173 reversion rate in subsequent model fits. Additionally, sero-prevalence was estimated for children aged 174 1-15 years. Given the lower likelihood of long-lived antibodies from previous malaria exposure, seropositivity in this age group is more likely to reflect recent infection.^{20,28} 175

Age-dependent antibody acquisition. Antibody acquisition models^{29,30} were used to estimate age-176 177 dependent changes in antibody levels. Two variants of the model were used - one assuming a constant 178 rate of increasing antibody levels with age and one assuming differing antibody acquisition rates 179 between age groups (Supplementary Methods). Area Under the Antibody Acquisition Curve (AUC) 180 values were calculated based on the model fit for each village and survey month, representing cumulative antibody levels across all ages.³¹ Within region AUCs were compared between the start 181 182 and end of transmission season as well as between regions at each time point. Strength of evidence 183 for observed differences are presented as p-values, derived from the posterior distributions of 184 predicted antibody levels over a specified age range.

185 Dry season antibody levels and odds of infection post-MDA. Individual antibody levels in April 2014 186 prior to MDA were assessed by comparing observed and expected MFI value as predicted by the 187 antibody acquisition fit for individuals in URR-South. For individuals with above average MFI values for 188 their age group, the difference between observed and expected logMFI was calculated and classified 189 to below or above median of residual MFI antibody response. Logistic regression was used to estimate 190 the odds of clinical malaria (passively detected via the health facility or study nurses in the community) 191 or asymptomatic *Pf* infection (actively detected using PCR from monthly survey samples) during the 192 transmission season following MDA (October - December 2014) amongst individuals below and above 193 median residual dry season antibody levels, compared to individuals at or below expected antibody 194 responses, allowing for clustering at the household/compound. Multivariate analyses also adjusted 195 for age, LLIN use, and MDA adherence using generalised linear mixed-effects models with the 'glm' 196 and 'glmer' functions in the 'lme4' v1.1-21 package in R version 3.6.1.

197 <u>Results</u>

198 Sero-prevalence in children by geographical region and transmission season. Variation in sero-199 prevalence between geographical region and transmission season differed by antigen. More 200 specifically, between July and December (start and end of the transmission season), seroprevalence 201 to Etramp5.Ag1 in children aged 1-15 years in the West Coast Region increased by 4.6% (95%Cl 1.0 -202 8.3) and by 2.9% (95%Cl 0.0 - 5.8) for *Pf*MSP1₁₉ (Table 1, Figure 2, Supplementary Table 1). In the URR, 203 there was statistically strong evidence for increases in under-15 sero-prevalence between July and 204 December for all antigens (Supplementary Table 1). Mean sero-prevalence in the URR in December 205 2014, the transmission season after MDA, was lower for *Pf*MSP1₁₉, *Pf*AMA1, Etramp5.Ag1, Rh2.2030 206 and EBA175, compared to December 2013 before implementation of MDA, but results were not 207 statistically significant (Supplementary Table 1).

Sero-conversion rate between geographical regions and transmission seasons. Differences in SCR
 between geographical region and transmission season varied by antigen (Figure 3, Supplementary

Table 2). In WCR, changes in antibody responses between transmission seasons were larger for *Pf*MSP1₁₉ (0·0147 increase in SCR between July and December) compared to *Pf*AMA1 (0·0007 increase in SCR). In URR, seasonal differences between July and December 2013 for both antigens were larger than the WCR, with an increase in *Pf*MSP1₁₉ SCR of 0·0405 and increase of 0·0301 in *Pf*AMA1 SCR. There was no significant change in SCR between December 2013 and April 2014 for either antigen.

215 At the start of the 2013 malaria transmission season (July), PfMSP119 SCR in URR was twice as high (SCR 0.0130, 95%CI 0.0088 – 0.0194) than in WCR (SCR 0.0067, 95%CI 0.0037 – 0.0123). After peak 216 217 transmission season, this difference was more pronounced, with PfMSP119 SCR 0.0214 (95%CI 0.0087 218 - 0.0530) in WCR compared to SCR 0.0535 (95%Cl 0.0344 - 0.0831) in URR. PfAMA1 SCR in the URR 219 was consistently higher than the WCR throughout the transmission season, with SCR 0.0159 (95%CI 220 0.0080 – 0.0239) and 0.0614 (95%CI 0.0509 – 0.0740) for WCR and URR, respectively, in July, and SCR 0.0166 (95%CI 0.0124 – 0.0224) and 0.0915 (95%CI 0.0738 – 0.1135) in WCR and URR, respectively, in 221 222 December. Increases in sero-prevalence in older age groups are not pronounced for markers 223 associated with short-lived antibody responses, which is an underlying assumption when using sero-224 catalytic models. Therefore, antibody acquisition models are used to assess age-adjusted changes in 225 antibody responses based on continuous data for markers of short-lived antibody responses.

226 Age-adjusted antibody acquisition by geographical region and transmission season. For antigens 227 associated with long-lived antibody responses (*Pf*MSP1₁₉ and *Pf*AMA1), differences in age-adjusted 228 antibody acquisition were observed between WCR and URR at the end of the 2013 transmission 229 season (December) (Figure 5, Supplementary Tables 8-9). For *Pf*MSP1₁₉ differences in geometric mean 230 antibody levels in children aged 1-15 years in URR were higher at the end of the transmission season 231 compared to the start of the season (p=0.03). Additionally, higher antibody levels to PfAMA1 in 1-15 232 year olds were observed in URR compared to WCR at the end of the transmission season (p<0.001). 233 No significant differences in antibody levels for *Pf*AMA1 were observed between the start and end of 234 transmission season in URR.

235 In contrast to PfMSP119 and PfAMA1, all serological markers associated with shorter-lived antibody 236 responses (Etramp5.Ag1, GEXP18, HSP.Ag1, EBA175, and Rh2.2030) showed higher antibody levels in 237 1-15 year olds in URR compared to WCR at the end of the transmission season (Figure 4, 238 Supplementary Tables 3-7). In URR, antibody responses to Etramp5.Ag1 increased between the start 239 and end of the transmission season amongst individuals 1-15 years (p=0.001). However, antibody 240 levels in 1-15 year olds for HSP40.Ag1 decreased between the start and end of the transmission season 241 in WCR (p=0.004). At the start of the transmission season, antibody levels to GEXP18 were higher in 242 URR compared to WCR (p=0.03). There were no within-region differences in antibody responses to 243 any of the antigens tested between the 2013 transmission season and the following dry season (April 244 2014).

245 Association between pre-MDA antibody levels and post-MDA malaria infection.

246 Decreases in under-15 sero-prevalence between pre- and post-MDA transmission seasons (December 2013 vs. December 2014) were only observed for GEXP18 (diff-3·4% 95%CI -9·2, 2·4) and HSP40.Ag1 247 248 (diff-2·1% 95%CI -7·0, 2·9), but differences were not statistically significant. After adjusting for age, LLIN use in the last 24 hours, and MDA compliance, individuals in the upper 50th percentile of above-249 250 average antibody levels to Etramp5.Ag1 for their age group in the dry season (April 2014, before the 251 implementation of MDA) had two-fold higher odds of clinical malaria (aOR 1.91 95%Cl 1.05 - 3.52, 252 p=0.04) in the 2014 transmission season (October – December) after MDA (Figure 6A, Supplementary 253 Table 10). Dry season antibody levels to Rh2.2030 were also moderately associated with increased 254 odds of clinical malaria (OR 1·75 95%CI 0·93 - 3·30, p=0·09) after MDA (Figure 6A, Supplementary Table 255 14), but statistical evidence was not strong. Similarly, there was a borderline association between 256 above average antibody levels to PfAMA1 in the dry season and increased odds of clinical malaria (OR 257 1.70 95%CI 0.97 - 2.98, p=0.07), but statistical association was weak after adjusting for age, LLIN use 258 and MDA compliancy (Figures 6A, Supplementary Table 16). Antibody responses to all other antigens

investigated were not associated with increased odds of infection post-MDA (Supplementary Tables11-15).

261 Discussion

262 In this study, spatio-temporal variations in serological responses were observed for several Pf 263 antigens, likely reflecting changes in malaria incidence as well as residual antibodies from prior 264 infection. In moderate to high transmission settings, higher antibody levels in the dry season due to prior exposure are common. However, the rate at which protective antibodies develop varies by 265 setting. Immunity to clinical malaria has been observed in children as young as 5 years^{32,33}, while in 266 other transmission ranges, immunity may only develop after 10 to 15 years of exposure.^{34,35} Children 267 268 can be a useful sentinel population for monitoring transmission, but the optimal age range for 269 surveillance depends on the historical patterns of transmission governing population antibody 270 responses. Most indicators and survey designs are associated with some bias affecting the accuracy of estimates. School surveys in South East Asia, where the distribution of malaria may be skewed 271 272 towards older age groups, may better reflect sero-incidence due to less childhood exposure compared 273 to sub-Saharan Africa. Serological surveillance protocols can therefore be combined with other 274 routine metrics to overcome potential sampling biases.

275 Differences in sero-conversion rates to PfMSP1₁₉ and PfAMA1 were observed between geographical 276 regions but not between transmission seasons. Long-lived antibody responses typically reflect past 277 exposure rather than incidence during a single transmission season. However, these markers have been shown to be sensitive to changes in transmission over longer periods of time in The Gambia.³⁶ 278 279 Antibody acquisition models can detect more subtle differences in the magnitude of antibody levels. 280 Five sero-incidence markers evaluated in this study - Etramp5.Ag1, GEXP18, HSP40.Ag1, EBA175, and Rh2.2030 - detected geographical differences in antibody acquisition. Additionally, Etramp5.Ag1 and 281 282 HSP40.Ag1 detected seasonal differences in high and low transmission settings. These findings align with previous microarray studies, where Etramp5.Ag1, GEXP18, HSP40 were amongst the top 10 283

serological markers out of 856 *Pf* antigens screened found to be most associated with recent episodes
 of clinical malaria in Uganda and Mali²¹.

Between December 2013 and April 2014, antibody levels did not decline significantly, indicating that 286 287 antibody decay probably occurs over a period longer than four months. This may be due to persistent 288 asymptomatic parasitaemia or infections occurring late in the transmission season. In The Gambia, 289 antibody decay in children has been observed for several antigens associated with protective 290 immunity (PfAMA1, PfMSP2, PfMSP1, EBA175), with antibody half-life estimated between 10 to 50 days^{37,38} and long-lived antibody secreting cells persisting for up to four years³⁸. However, antibody 291 half-lives vary between settings, ranging from 10-20 days in Kenya³⁹ and Ghana³⁸, 98 to 120 days in 292 Nigeria for EBA175 and Rh4.2⁴⁰, and up to 225 days in Cambodia⁴¹ and 7 years in Thailand⁴² for 293 294 PfMSP1₁₉. However, these studies focus on a limited number of antigens. Estimates of antibody longevity for a larger range of antigens can help inform optimal sampling strategies for future 295 296 serological surveillance using multiplex assay platforms. Studies in Mali have quantified antibody 297 responses to over 2,000 Pf antigens on protein microarray, observing rapid declines in antibody levels within six months.43 298

299 Above average antibody levels in the dry season before MDA was associated with increased odds of 300 clinical malaria following MDA. Associations were moderate for Rh2.2030 and PfAMA1, but individuals 301 with higher than average antibody levels against Etramp5.Ag1 had a two-fold higher odds of clinical 302 malaria post-MDA. It is possible that serology can identify individuals who are infected during the dry 303 season or experience a high frequency of exposure, leading to increased risk of clinical illness, despite 304 remaining below the detection limit of other diagnostics. Similar associations were observed using 305 parasitological endpoints, where individuals with Pf infection as measured by PCR in the dry season had increased odds of infection post MDA.²² This study was not designed to assess the effectiveness 306 307 of MDA using serological endpoints, and sample size may not be powered to draw strong conclusions. 308 Analysis of a larger set of antigens or grouping antibody data based on antigen expression or function

during the parasite life cycle may help delineate the wide range of responses with respect to malaria
 exposure, incidence, or immunity. Studies measuring persistent asymptomatic parasitaemia
 throughout the dry and wet seasons could further elucidate the dynamics between parasite density,
 immunity, and serological responses.

313 This study demonstrates that a diverse panel of serological markers can be used to monitor malaria 314 exposure (observed through long-lived antibody responses) and incidence (through shorter-lived antibody responses). Microarray studies evaluating the combined use of multiple serological markers 315 suggest that panels of at least five antigens confer greater diagnostic accuracy compared to a single 316 marker, while panels of more than 20 have only incremental improvements in accuracy^{21,44}. Between-317 318 antigen variation in antibody detection will also exist naturally; differences in the immunogenicity of 319 recombinant antigen constructs could be due to sequence selection or expression systems, or the choice of antigen isotypes or IgG subclasses. Multi-marker diagnostic panels may be better able to 320 321 capture the breadth of antibody responses in the population. This lends strong support for the 322 combined use of Pf antigens identified in this study in future diagnostic platforms. Evaluating their 323 accuracy in future intervention trials and surveillance studies, particularly cluster randomised trials, 324 can help establish standardised serological protocols usable across a variety of epidemiological 325 settings.

326 List of abbreviations

- 327 aOR: Adjusted odds ratio
- 328 AUC: Area Under the Antibody Acquisition Curve
- 329 CI: Confidence interval
- 330 DBS: Dried blood spot
- 331 DHA-PQ: Dihydroartemisnin-piperaquine
- 332 EBA175: Erythrocyte binding antigen 175 RIII-V
- 333 Etramp5.Ag1: Early transcribed membrane protein 5
- 334 GEE: Generalised estimating equations

- 335 GEXP18: Gametocyte export protein 18 (GEXP18)
- 336 HSP40.Ag1: Heat shock protein 40
- 337 IgG: Immunoglobulin
- 338 LLIN: Long-lasting insecticide treated net
- 339 MDA: Mass drug administration (MDA)
- 340 MFI: Median fluorescence intensity
- 341 PCD: Passive case detection
- 342 PCR: Polymerase chain reaction
- 343 Pf, P.falciparum: Plasmodium falciparum
- 344 *PfAMA1: P.falciparum* apical membrane antigen 1
- 345 *Pf*MSP1₁₉: *P.falciparum* merozoite surface antigen 1 19-kDa carboxy-terminal region
- 346 RDT: Rapid diagnostic test
- 347 Rh2.2030: Reticulocyte binding protein homologue 2
- 348 SCR: Sero-conversion rate
- 349 URR: Upper River Region, The Gambia
- 350 WCR: West Coast Region, The Gambia
- 351
- 352 Declaration of interests
- 353 Ethics approval and consent to participate
- This study was approved by the Gambia Government/MRC Joint Ethics Committee (SCC1318). Verbal
- 355 consent was first obtained at village sensitisation meetings, followed by individual written informed
- 356 consent for all participants. Parents/guardians provided written consent for children less than
- 357 17 years, and assent was obtained from children between 12 and 17 years.

358 Availability of data and materials

- 359 The datasets used and/or analysed during the current study are available from the corresponding
- 360 author on reasonable request.
- 361 Competing interests

362 All authors declare no competing interests.

363 Funding

- 364 This study was funded by the UK Medical Research Council (UKMRC) through the LSHTM Doctoral
- 365 Training Programme studentship received by LW. The funders had no role in the design of the study,
- 366 collection, analysis, interpretation of data or writing of the manuscript.

367 Author contributions

- 368 LW designed and coordinated the study, supervised and performed serological lab work, analysed the
- data, and wrote the manuscript. JM and MA supervised field data collection and laboratory work. SC
- and MB conducted the serological assays. KKAT and JB produced the antigens. KKAT and TH developed
- 371 the serological assay. JM, MA, UD, IK, and CD advised on study design, interpretation of findings, and
- 372 reviewed the manuscript. All authors read and approved the final manuscript.

373 References

1. WHO Global Malaria Programme. Malaria surveillance, monitoring & evaluation: a reference

375 *manual*. (World Health Organization, 2018).

- 2. Oesterholt, M. J. A. M. et al. Spatial and temporal variation in malaria transmission in a low
- 377 endemicity area in northern Tanzania. *Malar. J.* 5, 98 (2006).
- 378 3. Clark, T. D. *et al.* Factors determining the heterogeneity of malaria incidence in children in
- 379 Kampala, Uganda. J. Infect. Dis. **198**, 393–400 (2008).
- Bousema, T. *et al.* Identification of hot spots of malaria transmission for targeted malaria
 control. *J. Infect. Dis.* 201, 1764–74 (2010).
- 382 5. Bousema, T. *et al.* Hitting hotspots: spatial targeting of malaria for control and elimination.
- 383 PLoS Med. 9, e1001165 (2012).
- 384 6. Woolhouse, M. E. J. *et al.* Heterogeneities in the transmission of infectious agents:
- 385 Implications for the design of control programs. *Proc. Natl. Acad. Sci.* 94, 338–342 (1997).
- 386 7. Bousema, T. *et al.* The impact of hotspot-targeted interventions on malaria transmission:

387 study protocol for a cluster-randomized controlled trial. *Trials* **14**, 36 (2013).

- 388 8. Hayes, R. & Moulton, L. *Cluster Randomised Trials*. (Chapman & Hall/CRC Press, 2009).
- 389 9. Bautista, C. T. *et al.* Epidemiology and spatial analysis of malaria in the northern Peruvian
- 390 Amazon. *Am J Trop Med Hyg* **75**, 1216–1222 (2006).
- 10. Ernst, K. C., Adoka, S. O., Kowuor, D. O., Wilson, M. L. & John, C. C. Malaria hotspot areas in a
- 392 highland Kenya site are consistent in epidemic and non-epidemic years and are associated
- 393 with ecological factors. *Malar. J.* **5**, 78 (2006).
- Gaudart, J. *et al.* Space-time clustering of childhood malaria at the household level: a dynamic
 cohort in a Mali village. *BMC Public Health* 6, 286 (2006).
- WHO Global Malaria Programme. *A framework for malaria elimination*. (World Health
 Organization, 2017).
- 13. Noor, A. M. et al. The changing risk of Plasmodium falciparum malaria infection in Africa:

399		2000–10: a spatial and temporal analysis of transmission intensity. Lancet 383, 1739–1747
400		(2014).
401	14.	Thomas, C. J. & Lindsay, S. W. Local-scale variation in malaria infection amongst rural
402		Gambian children estimated by satellite remote sensing. Trans. R. Soc. Trop. Med. Hyg. 94,
403		159–63
404	15.	D'Alessandro, U. et al. Mortality and morbidity from malaria in Gambian children after
405		introduction of an impregnated bednet programme. Lancet 345 , 479–483 (1995).
406	16.	Snow, R. W., Rowan, K. M., Lindsay, S. W. & Greenwood, B. M. A trial of bed nets (mosquito
407		nets) as a malaria control strategy in a rural area of The Gambia, West Africa. Trans. R. Soc.
408		Trop. Med. Hyg. 82 , 212–5 (1988).
409	17.	Alonso, P. L. et al. A malaria control trial using insecticide-treated bed nets and targeted
410		chemoprophylaxis in a rural area of The Gambia, West Africa: 6. The impact of the
411		interventions on mortality and morbidity from malaria. Trans. R. Soc. Trop. Med. Hyg. 87, 37–
412		44 (1993).
413	18.	Mwesigwa, J. et al. On-going malaria transmission in The Gambia despite high coverage of
414		control interventions: a nationwide cross-sectional survey. Malar. J. 14, 314 (2015).
415	19.	Mwesigwa, J. et al. Residual malaria transmission dynamics varies across The Gambia despite
416		high coverage of control interventions. <i>PLoS One</i> 12 , e0187059 (2017).
417	20.	Okebe, J. et al. School-Based Countrywide Seroprevalence Survey Reveals Spatial
418		Heterogeneity in Malaria Transmission in the Gambia. PLoS One 9, e110926 (2014).
419	21.	Helb, D. A. et al. Novel serologic biomarkers provide accurate estimates of recent
420		Plasmodium falciparum exposure for individuals and communities. Proc. Natl. Acad. Sci. U. S.
421		<i>A</i> . 112 , E4438-47 (2015).
422	22.	Mwesigwa, J. et al. Mass Drug Administration With Dihydroartemisinin-piperaquine and
423		Malaria Transmission Dynamics in The Gambia: A Prospective Cohort Study. Clin. Infect. Dis.

424 **69**, 278–286 (2019).

- 425 23. Wu, L. *et al.* Optimisation and standardisation of a multiplex immunoassay of diverse
- 426 Plasmodium falciparum antigens to assess changes in malaria transmission using sero-
- 427 epidemiology. *Wellcome Open Res.* **4**, 26 (2019).
- 428 24. Snounou, G. Genotyping of Plasmodium spp. Nested PCR. *Methods Mol. Med.* **72**, 103–116
- 429 (2002).
- 430 25. Wu, L. et al. Optimisation and standardisation of a multiplex immunoassay of diverse
- 431 Plasmodium falciparum antigens to assess changes in malaria transmission using sero-
- 432 epidemiology. *Wellcome Open Res.* **4**, 26 (2019).
- 433 26. Stewart, L. *et al.* Rapid assessment of malaria transmission using age-specific sero-conversion
- 434 rates. *PLoS One* **4**, e6083 (2009).
- 435 27. Drakeley, C. J. et al. Estimating medium- and long-term trends in malaria transmission by
- using serological markers of malaria exposure. *Proc. Natl. Acad. Sci. U. S. A.* 102, 5108–13
 (2005).
- 438 28. Stevenson, J. C. *et al.* Reliability of School Surveys in Estimating Geographic Variation in
- 439 Malaria Transmission in the Western Kenyan Highlands. *PLoS One* **8**, e77641 (2013).
- 440 29. Weber, G. E. et al. Sero-catalytic and Antibody Acquisition Models to Estimate Differing
- 441 Malaria Transmission Intensities in Western Kenya. *Sci. Rep.* **7**, (2017).
- 442 30. Yman, V. *et al.* Antibody acquisition models: A new tool for serological surveillance of malaria
 443 transmission intensity. *Sci. Rep.* 6, 19472 (2016).
- 444 31. Arnold, B. F. et al. Measuring changes in transmission of neglected tropical diseases, malaria,
- and enteric pathogens from quantitative antibody levels. *PLoS Negl. Trop. Dis.* **11**, e0005616
 (2017).
- 447 32. Stanisic, D. I. *et al.* Acquisition of antibodies against Plasmodium falciparum merozoites and
- 448 malaria immunity in young children and the influence of age, force of infection, and
- 449 magnitude of response. *Infect. Immun.* **83**, 646–60 (2015).
- 450 33. Osier, F. H. A. *et al.* Breadth and Magnitude of Antibody Responses to Multiple Plasmodium

451	falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria. Infect.

452 *Immun.* **76**, 2240–2248 (2008).

- 453 34. Carneiro, I. et al. Age-Patterns of Malaria Vary with Severity, Transmission Intensity and
- 454 Seasonality in Sub-Saharan Africa: A Systematic Review and Pooled Analysis. *PLoS One* **5**,
- 455 e8988 (2010).
- 456 35. Griffin, J. T., Ferguson, N. M. & Ghani, A. C. Estimates of the changing age-burden of
- 457 Plasmodium falciparum malaria disease in sub-Saharan Africa. *Nat. Commun.* **5**, 3136 (2014).
- 458 36. van den Hoogen, L. L. *et al.* Serology describes a profile of declining malaria transmission in
 459 Farafenni, The Gambia. *Malar. J.* 14, 416 (2015).
- 460 37. Akpogheneta, O. J. *et al.* Duration of Naturally Acquired Antibody Responses to Blood-Stage
- 461 Plasmodium falciparum Is Age Dependent and Antigen Specific. *Infect. Immun.* 76, 1748–1755
 462 (2008).
- 463 38. White, M. T. *et al.* Dynamics of the Antibody Response to Plasmodium falciparum Infection in
 464 African Children. *J. Infect. Dis.* **210**, 1115–1122 (2014).
- 465 39. Kinyanjui, S. M., Conway, D. J., Lanar, D. E. & Marsh, K. IgG antibody responses to
- 466 Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. *Malar. J.*
- **6**, 82 (2007).
- 468 40. Ahmed Ismail, H. et al. Subclass responses and their half-lives for antibodies against EBA175
- 469 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria. *Malar. J.*
- **13**, 425 (2014).
- 471 41. Kerkhof, K. *et al.* Serological markers to measure recent changes in malaria at population
 472 level in Cambodia. *Malar. J.* **15**, 529 (2016).
- 473 42. Wipasa, J. *et al.* Long-Lived Antibody and B Cell Memory Responses to the Human Malaria
- 474 Parasites, Plasmodium falciparum and Plasmodium vivax. *PLoS Pathog.* **6**, e1000770 (2010).
- 475 43. Crompton, P. D. et al. A prospective analysis of the Ab response to Plasmodium falciparum
- 476 before and after a malaria season by protein microarray. *Proc. Natl. Acad. Sci. U. S. A.* **107**,

- 477 6958–63 (2010).
- 478 44. Longley, R. J. et al. Development and validation of serological markers for detecting recent
- 479 Plasmodium vivax infection. *Nat. Med.* **26**, 741–749 (2020).

480

481

Figure 1. Study timelines. Malaria Transmission Dynamics Study timeline shown in black and green. Serological study timeline shown in blue for West Coast and Upper River

Regions (low and moderate transmission settings, respectively). Samples for serological analysis were processed on the Luminex MAGPIX, samples from monthly surveys

were analysed using microscopy, rapid diagnostic tests (RDTs) and polymerase chain reaction (PCR). As part of the Malaria Transmission Dynamics Study, one round of mass

drug administration (MDA) was administered from May – June in both 2014 and 2015 (2015 not shown as no samples from this year were used for serological analysis).

Transmission season is approximately June - December each year.




Figure 2. Sero-prevalence in children ages 1-15 years by antigen, geographical region, and transmission season. Mean sero-prevalence estimates are shown for the West
 Coast Region (WCR) for July 2013 (light red) and December 2013 (dark red), and the Upper River Region (URR) for July 2013 (light blue), December 2013 (dark blue), April
 2014 (light green), and December 2014 (dark green). 95% confidence intervals are indicated by the vertical bars.





Table 2. Sero-prevalence in children aged 1-15 years by antigen, geographical region, and transmission season. Mean sero-prevalence estimates are shown for the West
 Coast Region (WCR) for July 2013 and December 2013, and the Upper River Region (URR) for July 2013, December 2013, April 2014, and December 2014. Mean and 95%
 confidence intervals (parentheses) are shown as percentages.


	PfMSP119	PfAMA1	Etramp5.Ag1	Rh2.2030	EBA175	GEXP18	HSP40.Ag1
West Coast Region							
July 2013 (n=314)	2.0% (1.0 - 3.1)	4.1% (2.7 - 5.5)	3.5% (2.2 - 4.9)	1.7% (0.8 - 2.6)	1.9% (0.9 - 2.8)	8.0% (6.1 - 9.9)	4.5% (3.0 - 5.9)
Dec 2013 (n=317)	4.9% (3.4 - 6.4)	4.2% (2.8 - 5.6)	8.2% (6.3 – 10.1)	2.1% (1.1 - 3.1)	1.1% (0.4 - 1.9)	9·9% (7·8 - 12·0)	4.8% (3.3 - 6.2)
Jpper River Region							
July 2013 (n=437)	3·3% (2·2 - 4·5)	14·4% (12·2 - 16·6)	5.5% (4.1 - 6.9)	6.8% (5.2 - 8.4)	5·4% (4·0 - 6·8)	16·2% (13·9 - 18·5)	7·3% (5·7 - 8·9)
Dec 2013 (n=390)	12·8% (10·8 - 14·9)	22.6% (20.1 - 25.2)	18·7% (16·3 - 21·1)	17·2% (14·9 - 19·6)	10.8% (8.9 - 12.7)	22.6% (20.1 - 25.2)	14·7% (12·5 - 16·9
Apr 2014 (n=504)	9.0% (7.4 – 10.5)	19·4% (17·3 - 21·6)	14.6% (12.7 - 16.5)	14.5% (12.5 - 16.4)	9.5% (7.9 – 11.1)	21.5% (19.3 - 23.7)	14·9% (13·0 - 16·9
Dec 2014 (n=449)	9·5% (7·8 – 11·2)	18·4% (16·1 - 20·6)	16·0% (13·8 - 18·1)	13·6% (11·6 - 15·6)	8·9% (7·2 – 10·5)	26·0% (23·4 - 28·6)	16.8% (14.6 - 19.0

Figure 3. *Pf*MSP1.19 and *Pf*AMA1 sero-conversion rates by transmission season and geographical region. Mean and 95% confidence intervals of sero-prevalence for each age group are shown as circles and vertical lines, respectively. Mean fit of the reverse catalytic model is shown as a solid line for the end of the transmission season (December 2013 and 2014) and dotted line for the dry season (April 2014) or start of the transmission season (July 2013). Shaded regions are the 95% credible interval of the model fit.



- 0 0

526 Figure 4. Age-dependent antibody acquisition for Etramp5.Ag1, GEXP18 and HSP40.Ag1 by geographical 527 region and transmission season. Mean and 95% confidence intervals of geometric mean antibody levels for 528 each age group are shown as circles and vertical lines, respectively. Median fit of the antibody acquisition model 529 is shown as a solid line for the end of the transmission season (December 2013 and 2014) and dotted line for 530 the dry season (April 2014) or start of the transmission season (July 2013). Shaded regions are the 95% credible 531 intervals of the model fit.






- 534
- 535
- 536

537 Figure 5. Age-dependent antibody acquisition for EBA175, Rh2.2030, PfMSP1.19 and PfAMA1 by geographical

region and transmission season. Mean and 95% confidence intervals of geometric mean antibody levels for
 each age group are shown as circles and vertical lines, respectively. Median fit of the antibody acquisition model
 is shown as a solid line for the end of the transmission season (December 2013 and 2014) and dotted line for
 the dry season (April 2014) or start of the transmission season (July 2013). Shaded regions are the 95% credible
 intervals of the model fit.



- 544 Figure 6. Association of pre-MDA dry season (April 2014) antibody levels and odds of (a) clinical malaria or (b)
- 545 asymptomatic infection, during transmission season post-MDA (December 2014). Odds ratios are adjusted for
- age, LLIN use and MDA compliancy. Clinical malaria is defined as clinical or RDT confirmed case, asymptomatic

547 infection is defined as PCR-positive and clinically or RDT-negative.

